Impact of Herbal Preparations on Outcomes of Highly Active Antiretroviral Therapy: A One-Year Prospective Cohort Study

  • Qi-jian Su
  • Ce Song
  • Zhen-zhen Lu
  • Zhen-wei Liu
  • Jian Xiao
  • Fa-sheng WuEmail author
Original Article



To investigate the impacts of two herbal preparations for human immunodeficiency virus/aquired immune deficiency syndrome (HIV/AIDS) patients, Shenling Fuzheng Capsule (参灵扶正胶囊, SLFZC) and Qingdu Capsule (清毒胶囊, QDC), on the efficacy of highly active antiretroviral therapy (HAART).


HIV/AIDS patients met the criteria were all enrolled in a 1-year cohort study, in which patients receiving HAART alone were designated as Group A, those receiving HAART in combination with SLFZC were designated as Group B, and those receiving HAART in combination with QDC were designated as Group C, 100 cases in each group. The dose of SLFZC was 1.48 g (4 capsules), 3 times daily, and QDC 1.56 g (4 capsules), 3 times daily. T cell subsets, HIV RNA and HIV-1 drug resistance were detected at enrollment and 1 year after treatment. Patients were followed up every 3 months, during which side-effects and other clinical data were recorded.


After 1-year treatment, the median increment in CD4 counts was 165.0, 178.0 and 145.0 cells/μL for Group A, B and C, respectively. HIV RNA was undetectable in 94% of patients in Group A, 96% in Group B and 92% in Group C. There were no differences regarding the increment in CD4 counts, HIV RNA and frequency of HIV-1 drug resistance mutations. Two of the 14 suspected side-effect symptoms, i.e. fatigue and dizziness, were lower in Groups B and C than in Group A (P<0.05, respectively)


SLFZC and QDC do not have a negative impact on immunological and virological response to HAART; however, these preparations are not as potent in reducing HAART-associated side-effects as anticipated.


human immunodeficiency syndrome aquired immune deficiency syndrome Chinese medicine Shenling Fuzheng Capsule Qingdu Capsule 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Liu J. The use of herbal medicines in early drug development for the treatment of HIV infections and AIDS. Expert Opin Investig Drugs 2007;16:1355–1364.CrossRefGoogle Scholar
  2. 2.
    Chinsembu KC. Ethnobotanical study of plants used in the management of HIV/AIDS-related diseases in Livingstone, Southern Province, Zambia. Evid Based Complement Alternat Med 2016;2016:4238625.CrossRefGoogle Scholar
  3. 3.
    Liu JP, Manheimer E, Yang M. Herbal medicines for treating HIV infection and AIDS. Cochrane Database Syst Rev 2005;20:CD003937.Google Scholar
  4. 4.
    Zou W, Liu Y, Wang J, Li H, Liao X. Traditional Chinese herbal medicines for treating HIV infections and AIDS. Evid Based Complement Alternat Med 2012;2012:950757.CrossRefGoogle Scholar
  5. 5.
    van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, De Smet PA, Burger DM. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev 2006;38:477–514.CrossRefGoogle Scholar
  6. 6.
    Thomford NE, Awortwe C, Dzobo K, Adu F, Chopera D, Wonkam A, et al. Inhibition of CYP2B6 by medicinal plant extracts: implication for use of efavirenz and nevirapine-based highly active anti-retroviral therapy (HAART) in resource-limited settings. Molecules 2016;21:211.CrossRefGoogle Scholar
  7. 7.
    Li X, Su QJ, Liang J, Deng X. Research on curative effect and safety of intervening asymptomatic HIV infection with traditional Chinese medicine. China J Tradit Chin Med Pharm (Chin) 2015;30:3520–3523.Google Scholar
  8. 8.
    Su QJ, Li YZ, Wu WQ, Lu ZZ, Zhang YP, Liu ZW, et al. Treating HIV/AIDS patients by Shenlin Fuzheng Capsule and Qingdu Capsule: an analysis of clinical effectiveness. Chin J Integr Tradit West Med (Chin) 2013;33:1476–1480.Google Scholar
  9. 9.
    Wen B, Li XJ, Liu ZW, Li X, Jiang F, Deng X. Exploration on influence of Shenling Fuzheng Capsule on patients with AIDS/HIV and chronic diarrhea after HAART based on theory of “winter disease cured in summer”. Liaoning J Tradit Chin Med (Chin) 2016;43:2302–2304.Google Scholar
  10. 10.
    Chen J, Zhang RF, Wang JR, Shen YZ, Liu L, Lu HZ. Efficacy and safety of highly active antiretroviral therapy combined with Tang Herb among HIV-infected patients. Shanghai Med Pharm J (Chin) 2014;35:17–19.Google Scholar
  11. 11.
    Yang JM, Ip SP, Xian Y, Zhao M, Lin ZX, Yeung JH, et al. Impact of the herbal medicine Sophora flavescens on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoprotein. PLoS One 2012;7:e31312.CrossRefGoogle Scholar
  12. 12.
    Zhang Y, Huang L, Bi H, Cui Y, Li J, Wang X, et al. Study of the upregulation of the activity of cytochrome P450 3A isoforms by Astragalus injection and Astragalus granules in rats and in cells. Eur J Drug Metab Pharmacokinet 2013;38:105–113.CrossRefGoogle Scholar

Copyright information

© The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Qi-jian Su
    • 1
  • Ce Song
    • 1
  • Zhen-zhen Lu
    • 1
    • 2
  • Zhen-wei Liu
    • 1
  • Jian Xiao
    • 3
  • Fa-sheng Wu
    • 1
    • 4
    Email author
  1. 1.Center for AIDS ResearchRuikang Hospital Affiliated to Guangxi University of Chinese MedicineNanningChina
  2. 2.Department of Chronic Noncommunicable Disease Prevention and ControlGuangxi Center for Disease Prevention and ControlNanningChina
  3. 3.School of Basic Medical ScienceGuangxi University of Chinese MedicineNanningChina
  4. 4.Department of OncologyRuikang Hospital Affiliated to Guangxi University of Chinese MedicineNanningChina

Personalised recommendations